Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-OLE long-term open-label extension of lerodalcibep
2023-510057-41-00Phase 3Completed
- Sponsor
- LIB Therapeutics
- Start
- Apr 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of lerodalcibep in familial hypercholesterolemia (FH), cardiac morbidity and hypercholesterolemia, sponsored by LIB Therapeutics. Started Apr 2024; status: completed.
02
Drugs
lerodalcibep
03
Conditions
familial hypercholesterolemia (FH)cardiac morbidityhypercholesterolemia
Beyond the preview
Go deeper on 2023-510057-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510057-41-00.